@article{petit_evolution_2017,
	title = {Évolution de la prise en charge médicamenteuse de la maladie d’{Alzheimer} en {EHPAD} : impact de la campagne médiatique contre les médicaments spécifiques de la maladie d’{Alzheimer}},
	volume = {43},
	issn = {0013-7006},
	shorttitle = {Évolution de la prise en charge médicamenteuse de la maladie d’{Alzheimer} en {EHPAD}},
	url = {https://www.sciencedirect.com/science/article/pii/S0013700616000452},
	doi = {10.1016/j.encep.2015.03.006},
	abstract = {Résumé
La maladie d’Alzheimer est une pathologie dont l’évolution est constamment défavorable et pour laquelle les traitements spécifiques sont sujets à polémique. La commission de la transparence de la Haute Autorité de santé (HAS) a rétrogradé leur service médical rendu en octobre 2011, le considérant comme faible. Notre étude, rétrospective, descriptive, transversale à 3 temps (T0 janvier 2011, T1 octobre 2011 et T2 juin 2012), a été menée au sein de 6 établissements d’hébergement pour personnes âgées dépendantes (EHPAD) de la métropole lilloise et a inclus 262 résidents. Son but était d’évaluer l’évolution de la consommation des traitements spécifiques de la maladie d’Alzheimer, mais aussi l’évolution de la qualité du suivi en consultation mémoire. Notre travail n’a pas montré d’impact majeur de la campagne médiatique contre les médicaments spécifiques de la maladie d’Alzheimer. Il existe néanmoins une tendance à la diminution de leur consommation chez les résidents déments en EHPAD, sans lien évident entre suivi en consultation spécialisée et prescription spécifique. Cette tendance demanderait à être confirmée par une étude de plus grande ampleur.
Context
Alzheimer's disease is a common disease in nursing homes. Evolution is constantly negative and specific treatments, which are only symptomatic, are subject to controversy. In a context of media exposure, the Transparency Committee of the Haute Autorité de santé (HAS) downgraded their medical service in October 2011, seeing it as weak.
Aim
Assess the evolution of the consumption of specific treatments for Alzheimer's disease; assess changes in the quality of monitoring in specific consultation.
Methods
This is a retrospective and descriptive study, cross-sectional in three times (T0 January 2011, T1 October 2011 and T2 June 2012), in 6 nursing homes of Lille and its surroundings.
Results
In total, 262 residents with dementia and present at least once during the three times of the study were included. Their mean age was 85.8 years. Among them, 40 \% had Alzheimer's disease clearly identified. At T0, 76.7 \% of patients present who were supposed to receive a specific treatment of Alzheimer's disease were actually receiving such treatment, 73.6 \% at T1 and 71.6 \% at T2. After 17 months of observation, the discontinuation rate of anticholinesterase was 34 \%, 24 \% for anti-glutamate. The monitoring in specific consultations decreased slightly between the three stages.
Conclusion
Our work did not show major impact of the media campaign against specific drugs for Alzheimer's disease. There is however a trend towards a decrease of their consumption in people with dementia living in nursing homes with no obvious link between monitoring in specific consultation and specific prescription. This trend would ask to be confirmed by a study on a larger scale.},
	language = {fr},
	number = {1},
	urldate = {2022-06-17},
	journal = {L'Encéphale},
	author = {Petit, A. -E. and Mangeard, H. and Chazard, E. and Puisieux, F.},
	month = feb,
	year = {2017},
	keywords = {Alzheimer's disease, Anti-cholinestérasiques, Cholinesterase inhibitors, EHPAD, Maladie d’Alzheimer, Nursing home},
	pages = {21--26},
}

{"_id":"DsXPu8zmCYrJsN7kW","bibbaseid":"petit-mangeard-chazard-puisieux-volutiondelapriseenchargemdicamenteusedelamaladiedalzheimerenehpadimpactdelacampagnemdiatiquecontrelesmdicamentsspcifiquesdelamaladiedalzheimer-2017","author_short":["Petit, A. -.","Mangeard, H.","Chazard, E.","Puisieux, F."],"bibdata":{"bibtype":"article","type":"article","title":"Évolution de la prise en charge médicamenteuse de la maladie d’Alzheimer en EHPAD : impact de la campagne médiatique contre les médicaments spécifiques de la maladie d’Alzheimer","volume":"43","issn":"0013-7006","shorttitle":"Évolution de la prise en charge médicamenteuse de la maladie d’Alzheimer en EHPAD","url":"https://www.sciencedirect.com/science/article/pii/S0013700616000452","doi":"10.1016/j.encep.2015.03.006","abstract":"Résumé La maladie d’Alzheimer est une pathologie dont l’évolution est constamment défavorable et pour laquelle les traitements spécifiques sont sujets à polémique. La commission de la transparence de la Haute Autorité de santé (HAS) a rétrogradé leur service médical rendu en octobre 2011, le considérant comme faible. Notre étude, rétrospective, descriptive, transversale à 3 temps (T0 janvier 2011, T1 octobre 2011 et T2 juin 2012), a été menée au sein de 6 établissements d’hébergement pour personnes âgées dépendantes (EHPAD) de la métropole lilloise et a inclus 262 résidents. Son but était d’évaluer l’évolution de la consommation des traitements spécifiques de la maladie d’Alzheimer, mais aussi l’évolution de la qualité du suivi en consultation mémoire. Notre travail n’a pas montré d’impact majeur de la campagne médiatique contre les médicaments spécifiques de la maladie d’Alzheimer. Il existe néanmoins une tendance à la diminution de leur consommation chez les résidents déments en EHPAD, sans lien évident entre suivi en consultation spécialisée et prescription spécifique. Cette tendance demanderait à être confirmée par une étude de plus grande ampleur. Context Alzheimer's disease is a common disease in nursing homes. Evolution is constantly negative and specific treatments, which are only symptomatic, are subject to controversy. In a context of media exposure, the Transparency Committee of the Haute Autorité de santé (HAS) downgraded their medical service in October 2011, seeing it as weak. Aim Assess the evolution of the consumption of specific treatments for Alzheimer's disease; assess changes in the quality of monitoring in specific consultation. Methods This is a retrospective and descriptive study, cross-sectional in three times (T0 January 2011, T1 October 2011 and T2 June 2012), in 6 nursing homes of Lille and its surroundings. Results In total, 262 residents with dementia and present at least once during the three times of the study were included. Their mean age was 85.8 years. Among them, 40 % had Alzheimer's disease clearly identified. At T0, 76.7 % of patients present who were supposed to receive a specific treatment of Alzheimer's disease were actually receiving such treatment, 73.6 % at T1 and 71.6 % at T2. After 17 months of observation, the discontinuation rate of anticholinesterase was 34 %, 24 % for anti-glutamate. The monitoring in specific consultations decreased slightly between the three stages. Conclusion Our work did not show major impact of the media campaign against specific drugs for Alzheimer's disease. There is however a trend towards a decrease of their consumption in people with dementia living in nursing homes with no obvious link between monitoring in specific consultation and specific prescription. This trend would ask to be confirmed by a study on a larger scale.","language":"fr","number":"1","urldate":"2022-06-17","journal":"L'Encéphale","author":[{"propositions":[],"lastnames":["Petit"],"firstnames":["A.","-E."],"suffixes":[]},{"propositions":[],"lastnames":["Mangeard"],"firstnames":["H."],"suffixes":[]},{"propositions":[],"lastnames":["Chazard"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Puisieux"],"firstnames":["F."],"suffixes":[]}],"month":"February","year":"2017","keywords":"Alzheimer's disease, Anti-cholinestérasiques, Cholinesterase inhibitors, EHPAD, Maladie d’Alzheimer, Nursing home","pages":"21–26","bibtex":"@article{petit_evolution_2017,\n\ttitle = {Évolution de la prise en charge médicamenteuse de la maladie d’{Alzheimer} en {EHPAD} : impact de la campagne médiatique contre les médicaments spécifiques de la maladie d’{Alzheimer}},\n\tvolume = {43},\n\tissn = {0013-7006},\n\tshorttitle = {Évolution de la prise en charge médicamenteuse de la maladie d’{Alzheimer} en {EHPAD}},\n\turl = {https://www.sciencedirect.com/science/article/pii/S0013700616000452},\n\tdoi = {10.1016/j.encep.2015.03.006},\n\tabstract = {Résumé\nLa maladie d’Alzheimer est une pathologie dont l’évolution est constamment défavorable et pour laquelle les traitements spécifiques sont sujets à polémique. La commission de la transparence de la Haute Autorité de santé (HAS) a rétrogradé leur service médical rendu en octobre 2011, le considérant comme faible. Notre étude, rétrospective, descriptive, transversale à 3 temps (T0 janvier 2011, T1 octobre 2011 et T2 juin 2012), a été menée au sein de 6 établissements d’hébergement pour personnes âgées dépendantes (EHPAD) de la métropole lilloise et a inclus 262 résidents. Son but était d’évaluer l’évolution de la consommation des traitements spécifiques de la maladie d’Alzheimer, mais aussi l’évolution de la qualité du suivi en consultation mémoire. Notre travail n’a pas montré d’impact majeur de la campagne médiatique contre les médicaments spécifiques de la maladie d’Alzheimer. Il existe néanmoins une tendance à la diminution de leur consommation chez les résidents déments en EHPAD, sans lien évident entre suivi en consultation spécialisée et prescription spécifique. Cette tendance demanderait à être confirmée par une étude de plus grande ampleur.\nContext\nAlzheimer's disease is a common disease in nursing homes. Evolution is constantly negative and specific treatments, which are only symptomatic, are subject to controversy. In a context of media exposure, the Transparency Committee of the Haute Autorité de santé (HAS) downgraded their medical service in October 2011, seeing it as weak.\nAim\nAssess the evolution of the consumption of specific treatments for Alzheimer's disease; assess changes in the quality of monitoring in specific consultation.\nMethods\nThis is a retrospective and descriptive study, cross-sectional in three times (T0 January 2011, T1 October 2011 and T2 June 2012), in 6 nursing homes of Lille and its surroundings.\nResults\nIn total, 262 residents with dementia and present at least once during the three times of the study were included. Their mean age was 85.8 years. Among them, 40 \\% had Alzheimer's disease clearly identified. At T0, 76.7 \\% of patients present who were supposed to receive a specific treatment of Alzheimer's disease were actually receiving such treatment, 73.6 \\% at T1 and 71.6 \\% at T2. After 17 months of observation, the discontinuation rate of anticholinesterase was 34 \\%, 24 \\% for anti-glutamate. The monitoring in specific consultations decreased slightly between the three stages.\nConclusion\nOur work did not show major impact of the media campaign against specific drugs for Alzheimer's disease. There is however a trend towards a decrease of their consumption in people with dementia living in nursing homes with no obvious link between monitoring in specific consultation and specific prescription. This trend would ask to be confirmed by a study on a larger scale.},\n\tlanguage = {fr},\n\tnumber = {1},\n\turldate = {2022-06-17},\n\tjournal = {L'Encéphale},\n\tauthor = {Petit, A. -E. and Mangeard, H. and Chazard, E. and Puisieux, F.},\n\tmonth = feb,\n\tyear = {2017},\n\tkeywords = {Alzheimer's disease, Anti-cholinestérasiques, Cholinesterase inhibitors, EHPAD, Maladie d’Alzheimer, Nursing home},\n\tpages = {21--26},\n}\n\n","author_short":["Petit, A. -.","Mangeard, H.","Chazard, E.","Puisieux, F."],"key":"petit_evolution_2017","id":"petit_evolution_2017","bibbaseid":"petit-mangeard-chazard-puisieux-volutiondelapriseenchargemdicamenteusedelamaladiedalzheimerenehpadimpactdelacampagnemdiatiquecontrelesmdicamentsspcifiquesdelamaladiedalzheimer-2017","role":"author","urls":{"Paper":"https://www.sciencedirect.com/science/article/pii/S0013700616000452"},"keyword":["Alzheimer's disease","Anti-cholinestérasiques","Cholinesterase inhibitors","EHPAD","Maladie d’Alzheimer","Nursing home"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/groups/2266462/items?key=MgKoXciZhHmJ176339ZdCynJ&format=bibtex&limit=100","dataSources":["PSBFFbnPhFKwYx7yq"],"keywords":["alzheimer's disease","anti-cholinestérasiques","cholinesterase inhibitors","ehpad","maladie d’alzheimer","nursing home"],"search_terms":["volution","prise","charge","dicamenteuse","maladie","alzheimer","ehpad","impact","campagne","diatique","contre","les","dicaments","cifiques","maladie","alzheimer","petit","mangeard","chazard","puisieux"],"title":"Évolution de la prise en charge médicamenteuse de la maladie d’Alzheimer en EHPAD : impact de la campagne médiatique contre les médicaments spécifiques de la maladie d’Alzheimer","year":2017}